Identifying immune cell changes in chronic lung diseases using advanced sequencing techniques.
Official title: Identifying Disease-Specific Immune Cell Shifts in Chronic Fibrotic Interstitial Lung Diseases with Single-Cell RNA Sequencing
Funded at Yale University · NIH-11017010 · Data updated 2026-11-12
This study is looking at how immune cells change in people with chronic lung diseases to find new ways to diagnose and treat conditions like idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis, using a simple blood test.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | February 16, 2022 |
| Project end | February 15, 2026 |
| Funding year | 2025 |
| Award (this year) | $53,974 |
| NIH project number | 5F30HL162459-04 |
| Project ID | NIH-11017010 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with chronic fibrotic interstitial lung diseases, particularly those experiencing symptoms related to these conditions.
✕Less likely to help
Patients with acute lung conditions or those without a diagnosis of interstitial lung disease may not benefit from this research.
What this research studies
This research investigates how immune cells change in patients with chronic fibrotic interstitial lung diseases (ILDs) by using a cutting-edge technique called single-cell RNA sequencing. The goal is to better understand the specific immune responses associated with different types of ILDs, which can help in making accurate diagnoses. By analyzing blood samples, the researchers aim to identify unique biomarkers that can distinguish between various forms of ILDs, such as idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. This minimally invasive approach could lead to improved diagnostic methods and tailored treatments for patients.
Why it matters
Potential benefit: If successful, this research could lead to more accurate diagnoses and better treatment options for patients with chronic fibrotic interstitial lung diseases.
How similar studies have gone: Previous research has shown promise in using single-cell RNA sequencing to identify immune cell changes in various diseases, indicating that this approach could be effective in the context of interstitial lung diseases as well.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Zhao, Amy Yue-Ting — Yale University
- Study coordinator: Zhao, Amy Yue-Ting
Related research
Other NIH-funded projects on the same topics.
-
How lung cells and their surroundings drive fibrosis in interstitial lung diseases
A study to understand how airway cells, surrounding tissue, and their environment contribute to progressive scarring in interstitial lung diseases.
-
Quantitative Ultrasound for Lung Diseases in People
A new ultrasound approach to measure how bad heart- or fibrosis-related lung problems are, using real-time, noninvasive imaging in people.
-
Better Lung Imaging for Conditions like Pulmonary Fibrosis
This work explores a new ultrasound method to better track lung conditions like heart failure-related fluid buildup and idiopathic pulmonary fibrosis in people.
-
How lung cell and tissue interactions cause scarring in interstitial lung disease
This project looks at how injured lung lining cells talk with nearby cells and the surrounding tissue to cause scarring in people with interstitial lung disease.
-
Investigating personalized treatment options for Idiopathic Pulmonary Fibrosis using genetic information.
This study is looking to help people with Idiopathic Pulmonary Fibrosis (IPF) by using their genetic information to find the best treatments for them, so they can get care that’s more personalized and effective.
-
Investigating personalized treatment options for Idiopathic Pulmonary Fibrosis using genetic information
This study is looking to make treatments for Idiopathic Pulmonary Fibrosis (IPF) better by using genetic information to find out how different people respond to medications like N-Acetylcysteine, so that doctors can provide more personalized care for patients with lung diseases.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.